FAQ/Help |
Calendar |
Search |
Today's Posts |
|
10-06-2010, 09:51 PM | #1 | ||
|
|||
Junior Member
|
That was four years ago. Have they started a trial yet?
Quote:
|
||
Reply With Quote |
10-06-2010, 10:13 PM | #2 | |||
|
||||
Senior Member
|
Yep, that's why I wondered whether this was just old but updated news which essentially it is. Researchers were onto this four years go, but I guess the genetic link and the master switch thing are the key new developments.
The brand name is Actos. I guess this is one of the few that doesn't have nasty cardiac side effects. There is a really great article in Nature on all of this. You'll love this quote: ... a clinical trial to test Actos in patients with Parkinson's disease has already been approved by regulators. Nature article No trial to date that I can find at clinicaltrials.gov Laura |
|||
Reply With Quote |
"Thanks for this!" says: | imark3000 (10-07-2010) |
10-06-2010, 10:20 PM | #3 | ||
|
|||
Junior Member
|
Couldn't find anything.
There is a new trial of Byetta (another Diabetes drug) that is taking place in England. But I don't know if it stimulates this particular protein. The link you provided says that MJFF provided some funding for the study. I don't get why four years have gone by without a trial. Cal Quote:
|
||
Reply With Quote |
10-08-2010, 09:25 AM | #4 | ||
|
|||
In Remembrance
|
Published online 6 October 2010 | Nature | doi:10.1038/news.2010.518
News Damaged cell powerhouses linked to Parkinson's New uses for old drugs Such drugs have already been widely pursued as potential therapies for type 2 diabetes, and some have already been approved for that use. Avandia (rosiglitazone), a diabetes drug recently pulled from the European market because it raises the risk of heart attack, activates a key protein in the PGC-1α pathway. But a related drug called Actos (pioglitazone) has not been firmly linked to heart attack and remains in use. Beal says that a clinical trial to test Actos in patients with Parkinson's disease has already been approved by regulators. http://www.nature.com/news/2010/1010....2010.518.html no mention of metformin altho it sounds safe for diabetes.
__________________
paula "Time is not neutral for those who have pd or for those who will get it." Last edited by paula_w; 10-08-2010 at 09:29 AM. Reason: duh just read laura's again...same study |
||
Reply With Quote |
"Thanks for this!" says: | caldeerster (10-08-2010) |
10-08-2010, 11:21 AM | #5 | |||
|
||||
Senior Member
|
Quote:
We're onto that, but Actos was first brought up in the news four years ago! MFJJ funded the initial study and there has been no movement on it. I searched for the lead researchers name "Marina Emborg" and it doesn't even look like it is on her radar...another possible major treatment sucked into the black hole. If Debi Brooks is reading...help! Laura |
|||
Reply With Quote |
10-08-2010, 04:21 PM | #6 | ||
|
|||
Junior Member
|
Thanks Laura
Cal Quote:
|
||
Reply With Quote |
10-08-2010, 08:18 PM | #7 | ||
|
|||
In Remembrance
|
...debi brooks and katie hood; hope they know, could it possibly be under wraps? Does it involve a separate patent?
__________________
paula "Time is not neutral for those who have pd or for those who will get it." |
||
Reply With Quote |
10-16-2010, 06:58 PM | #8 | |||
|
||||
Member
|
Quote:
Thanks for including the "Nature" article. If I was reading it correctly, the regulators, referred to in the article, are in Europe. So perhaps there is a trial going on there. I am definitely going to look into Actos after seeing the Science Daily article today on research from Harvard. |
|||
Reply With Quote |
07-13-2011, 11:23 AM | #9 | ||
|
|||
Banned User
|
It would be important to realize that activation of PGC-1 {alpha} and {beta} has severe side effects that can occur during a treatment:
Below a summary about the possible problems: - When PGC-1 {alpha} or {beta} are higher in the muscle, tumor necrosis factor {alpha} (TNF {alpha}) is elevated. More TNF {alpha}, a mediator of inflammation, is secreted into the blood (cf. Olesen J et al; Medicine & Science in Sports & Exercise: October 2010 - Volume 42 - Issue 10 - p 58. - The same article shows this at basal levels and that it worsens following injection of TNF into muscle. - When PGC-1 is elevated more lipids are accumulating in muscle. People can become obese. Lipids often induce inflammation (cf. Summermatter S et al; Journal of biological chemistry: October 2010 22;285(43):32793-800) - Then PGC-1 can even induce diabetes when too high (cf. Miura S, Journal of biological chemistry: August 2003 15;278(33):31385-90.) - High PGC-1 {alpha} and {beta} levels, basal and after stimulation by TNF or Lipopolysaccharide (LPS) lead to high expression and release of inflammatory IL (interleukin) and of macrophage infiltration as indicated by CD (cluster of differentiation) All this should be kept in mind. Maybe it's still ok to develop drugs that promote PGC-1, but it should be considered that this can have these side effects. |
||
Reply With Quote |
"Thanks for this!" says: | paula_w (07-13-2011) |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
A Definition Question- re meaning of "Full Body RSD" and "Internal RSD" ?? | Reflex Sympathetic Dystrophy (RSD and CRPS) | |||
Statins & Niacin - (and regarding "No-Flush" vs "Sustained Release" | Vitamins, Nutrients, Herbs and Supplements | |||
Actor Patrick Swayze, star of "Dirty Dancing" and "Ghost," | The Stumble Inn | |||
"Hundreds Dead" in Failed Diabetes Drug Trial | Diabetes / Insulin Resistance / Metabolic Syndrome | |||
"Instant Karma" - the Voices of Apathy -"Coulter and Limbaugh" | Parkinson's Disease |